Directorate Change

Stem Cell Sciences plc
09 October 2006



Embargoed until 07.00                                             9 October 2006


                             Stem Cell Sciences plc
                     ("Stem Cell Sciences" or "the Group")

           Stem Cell Sciences' Board Strengthened for US Development

Stem Cell Sciences plc (AIM:STEM), the global biotechnology company focused on
the commercialisation of stem cells and stem cell technologies in research and
novel cell-based therapies, is pleased to announce the appointment of David A
Dodd to the Stem Cell Sciences' Board as Non-executive Director with immediate
effect.

Mr. Dodd, aged 57, brings a wealth of commercial and corporate Life Sciences
experience to the Group. He was President, Chief Executive Officer and Director
of NASDAQ quoted Serologicals Corporation until it was acquired by the Millipore
Corporation on 14 July 2006. During Mr. Dodd's six year leadership, the value of
Serologicals Corporation increased from $85 million to $1.4 billion.

From August 1995 until June 2000, he served as President and Chief Executive
Officer of Solvay Pharmaceuticals Inc. and as a member of the Management Board
for the Pharmaceutical Sector for Solvay S.A. Mr. Dodd was also Chairman of the
Board of Unimed Pharmaceuticals, Inc., a subsidiary of Solvay Pharmaceuticals.
Prior to joining Solvay, he served in a number of management and executive
positions with major life science corporations, including Wyeth, Bristol-Myers
Squibb, and Abbott Laboratories.

Mr. Dodd currently serves on the board of a number of not-for-profit
organisations including; the Board of the Georgia Biomedical Partnership, as
Immediate Past-Chair; on the Board of the Southern BioAlliance; and, is Chairman
of the Board of the American Foundation for Suicide Prevention. Additionally he
sits on the Advisory Board of the Institute for Bioengineering and Bioscience,
Georgia Tech/Emory University and the International Development Board, of the
University of Dundee, Scotland.

He recently was awarded the 2005 GBP Biomedical Industry Growth Award for his
efforts in promoting Georgia's life sciences industry. In addition, Mr. Dodd
received the 2005 Oglethorpe Award from the Atlanta Chapter of the British
American Business Group, in recognition of his ongoing leadership in fostering
business relationships between the U.S. and the United Kingdom.

David holds a Bachelor of Science and Master of Science from Georgia State
University and completed the Harvard Business School Advanced Management
Program.

Dr Michael Dexter, Chairman of Stem Cell Sciences said: "The appointment of
David brings considerable strengths to our Board and will greatly assist us in
meeting our targets for expansion into US markets."

Commenting on his appointment David Dodd said: "I am delighted to be joining the
Stem Cell Sciences' team. I look forward to bringing my own experience to the
Board and assisting Stem Cell Sciences in the development of the Group's
exciting plans for the business, particularly in the United States where we are
seeing very exciting times for stem cell research."

Stem Cell Sciences' Chief Executive, Peter Mountford said: "We are delighted
that David has accepted our invitation to join the Board. I am sure his
extensive knowledge of the life science industry and depth of experience in
international business will add great value to our global business initiative."

Current Commercial Appointments held

--------------------------------------------------------------------------------
Company Name                                          Position         Appointed   
--------------------------------------------------------------------------------
None                                                                 
--------------------------------------------------------------------------------

Past Appointments Held

--------------------------------------------------------------------------------
Name                                  Position       Appointed          Resigned 
--------------------------------------------------------------------------------
Serologicals Corporation        President, CEO       June 2000         July 2006
                                  and Director                       
--------------------------------------------------------------------------------
Solvay Pharmaceuticals Inc       President and     August 1995         June 2000
                                           CEO                                
--------------------------------------------------------------------------------
Unimed Pharmaceuticals Inc            Chairman       July 1995         June 2000
--------------------------------------------------------------------------------
American Home Products/Wyeth       Senior Vice      March 1995         July 1995  
Ayerst Laboratories                  President                             
--------------------------------------------------------------------------------
American Home Products/Wyeth    Vice President   February 1991          Promoted   
Ayerst Laboratories                and General                        March 1995 
                                       Manager                              
--------------------------------------------------------------------------------
Bristol Myers Squibb/Mead      General Manager     August 1990    February  1991   
Johnson Laboratories Division                                   
--------------------------------------------------------------------------------
Bristol Myers Squibb/Mead          Director of    October 1986          Promoted   
Johnson Laboratories Division        Marketing                       August 1990
--------------------------------------------------------------------------------

                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc                                             0131 662 9829
Michael Dexter, Chairman
Peter Mountford, Chief Executive Officer
Hugh Ilyine, Chief Operating Officer
Sue Furber, Director of Finance & Company Secretary

Weber Shandwick | Square Mile                                      020 7067 0700
James White

Notes to Editors

Stem Cell Sciences plc

Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company
providing products in the burgeoning stem cell research and drug discovery
markets, in addition to the targeted development of cell-based therapies for
neurodegenerative disease and injury.

The Company has established a leading intellectual property (IP) and technology
portfolio that provides a single platform of stem cells and stem cell
technologies for both research and clinical application. Revenue streams and
technology development for the scaled production of stem cells in basic research
and drug discovery underpin the company's longer term plans to be a leading
provider of cell-based therapeutics.

SCS' principal focus is in neurological disease. Total revenues for the global
neurotech market, including pharmaceuticals, devices and diagnostics, grew 10%
in 2005 to US$110 billion*.

SCS operates as a global group with laboratories in Scotland, Japan and
Australia, each of which is affiliated with an academic centre of excellence.
These include the Institute of Stem Cell Research (ISCR), Edinburgh, UK; RIKEN
Centre for Development Biology, Kobe, Japan and the Australian Stem Cell Centre,
Melbourne, Australia.

SCS has four business units focused on key sustainable business strategies.

SC Proven(R) provides cell culture media (liquid formulations) and reagents that
enable the growth and differentiation of stem cells. The first commercially
available product, a novel, serum free, stem cell growth medium, has been
exclusively licensed for manufacture and marketing to Chemicon International
(part of the Millipore Group).

SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome
Entry Site (IRES) and Stem Cell Selection, for application in laboratory-based
research and discovery. SCS has licensed technology to major pharmaceutical and
biotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc and
Lexicon Genetics Inc.

SC Services provides specialised stem cell production for basic research and
drug discovery, including high-throughput applications.

SC Therapies goal is to develop safe and effective cell-based therapies for
currently incurable diseases. SCS is evaluating proprietary technologies in
early stage research for future cell therapy applications.

*Neurotech Insights, Volume 2/3 April 30 2006.

Serologicals Corporation

Serologicals Corporation, headquartered in Atlanta, Georgia, was a global
provider of biological products, enabling technologies and custom services to
life science companies and research organizations. The Company's diverse
customer base included major life science companies and leading research
institutions. Prior to its recent purchase, Serologicals had approximately 1000
employees worldwide, and its shares were traded on the NASDAQ national stock
market under the symbol SERO.





                      This information is provided by RNS
            The company news service from the London Stock Exchange